The risk of pharma companies defaulting on debt; FDA reviewing Mirati's lung cancer drug

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Pharma companies rarely default on debt, but it remains a risk factor for investors By Ed Silverman Mike Reddy for STAT The analysis “highlights risk factors that might be not be on their radar or are otherwise underappreciated,” said David Kaplan of S&P. Read More Senate narrowly confirms Robert Califf to lead the FDA By Nicholas Florko Manuel Balce Ceneta/AP The Senate on Tuesday narrowly confirmed Robert Califf as the commissioner of the Food and Drug Administration. Read More STAT+: The FDA is reviewing Mirati's KRAS-blocking lung cancer drug — but taking longer to do it By Adam Feuerstein Andy Wong/AP The FDA accepted Mirati's application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped. Read More Sponsor content by ICON CLINICAL RESEARCH Advanced clinical solutions powered by healthcare intelligence — delivered seamlessly ICON is the world's largest and most comprehensive clinical research organization, powered by Healthcare Intelligence. Leveraging their human expertise, robust clinical capabilities, and insightful data resources, ICON is expanding the possibilities of clinical research without sacrificing the vital, day-to-day functions of today's CROs. Learn more. Opinion: Welcome back to the FDA, Robert Califf. Let's get to work on your big idea By Elizabeth Baker and Eryn Slankster-Schmierer Pablo Martinez Monsivais/AP An idea from Califf's earlier tenure he should pursue now: make data submitted to the FDA as part of drug development be publicly available. Read More STAT+: Private equity firms are cashing in on the travel nursing business that has boomed during the pandemic By Rachel Cohrs David Goldman/AP Private equity firms are buying up travel nurse staffing agencies as their business has boomed during the pandemic. Read More Tuesday, February 15, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser